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This review addresses the unresolved aetiology of several nephropathies and associated upper tract tumours 
diagnosed all over the world, but especially in the Balkan regions. Studies conducted over the last 35 
years point to mycotoxins, mainly ochratoxin A (OTA) as the main culprit. Recent theories however have 
implicated aristolochic acids (AA). The aim of this review is to put forward arguments in favour of the 
mycotoxin theory and to show the incoherence of the AA theory. It discusses the differences between the 
epidemiology of Balkan endemic nephropathy (BEN) and aristolochic acid nephropathy (AAN); OTA 
and AA carcinogenicity; clinical and pathological effects induced by OTA and AA; sources of OTA 
contamination (food, air, drinking water); OTA- and AA-DNA adduct formation; the role of genetic 
polymorphisms ; and the risk for young children.
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Balkan endemic nephropathy (BEN) is a familial 
chronic tubulointerstitial disease with insidious 
onset and slow progression to terminal renal 
failure unaccompanied by salt retention or early 
hypertension (1) (Table 1). It mainly affects people 
living along the tributaries of the Danube River in 
Bosnia, Bulgaria, Croatia, Romania and Serbia. 
BEN and the associated urothelial tract tumour 
(UTT) were fi rst described in 1956 in Bulgaria, and 
then in Serbia in 1957 (2, 3).
BEN has a familial character. It may affect 
several generations in a single household. Affected 
and spared households live one next to another. 
This is why the incidence of BEN is uneven within 
and between affected villages. They are sometimes 
separated from unaffected villages by only a few 
kilometres. So far, the disease has been identifi ed 
in 142 villages in Bosnia, Croatia, and Serbia, with 
local prevalence ranging between 0.5 % and 4 %, 
in 40 villages in Bulgaria with mean morbidity rate 
of 3 %, and in 40 villages and small towns of the 
Romanian districts of Mehedinţi and Caraş-Severin, 
with prevalence of over 2 % (4). A high prevalence 
of tumours of the renal pelvis and ureter (upper 
urothelial cancer, UUC) was described in patients 
with BEN and in affected families. It was up to 
100 times higher than in non-endemic areas (4-7). 
Studies conducted in villages around Slavonski 
Brod, Croatia, pointed to environmental factors 
as key determinants of individual susceptibility 
to BEN (8). Patients with UUC are at risk of 
developing bladder tumours, with an estimated 
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occurrence of 15 % to 50 %. Bladder Transitional 
Cell Carcinoma (TCC) usually appears within fi ve 
years. Some patients develop pelvis pain and bone 
metastases (9). The link between BEN and UTT 
can be explained by insult from an environmental 
contaminant (10).
In 1972, Akhmeteli (11) suggested that fungal 
toxins were involved in the aetiology of BEN, 
notably ochratoxin A (OTA) (12). Although a 
number of fi ndings support the mycotoxin theory, 
the implication of aristolochic acid (AA) has 
emerged recently as an alternative (13). The aim of 
this paper is to review arguments in favour or against 
either theory of the development of nephropathies 
and associated urothelial tract tumours in the Balkan 
regions and other parts of the world.
EPIDEMIOLOGICAL DIFFERENCES 
BETWEEN BEN AND AAN
BEN occurs exclusively in rural population. In 
1957-1960, the average age of patients at death was 
45.1 years while in 1991-2002 it was 69.2 years. 
Although increased life expectancy, similar to that 
of the general population in the area, is probably 
owed to lower exposure to the toxic compound, 
there are still new cases of the disease and it has 
not disappeared (7). BEN neither expands nor 
disappears from endemic areas (14). The sex ratio in 
BEN is approximately 1:1, while aristolochic acid 
nephropathy (AAN) is exclusively seen in women. 
The length of exposure before the appearance of 
clinical signs is quite different between BEN and 
AAN. BEN does not occur in children, but people 
who left the endemic area after over a decade of 
residence also develop BEN. This suggests that the 
causative agent is slow-acting, and that exposure had 
continued for many years. In contrast, patients with 
AAN often show a rapid deterioration in the renal 
function, with doubling of creatinine levels within 
about three months. The development of urinary 
tract malignancy is also much longer in BEN (6) 
than in AAN (15). The latency of malignancies is 
20 to 27 years after the diagnosis of BEN, and 2 to 
6 years after the diagnosis of AAN.
Until now, only one paper has implicated 
exposure to AA in a BEN area, based on a 
questionnaire about the presence of birthwort 
(Aristolochia clematitis L.) in local fi elds (13). 
Since birthwort was not mentioned before as 
a potential risk factor for the development of 
nephropathy, the importance of its presence in the 
fi eld is not clear. The conclusion drawn in this paper 
implicating AA in BEN and associated UTT calls 
for scepticism for several reasons:
(i) wheat is typically harvested in mid-summer 
when seeds of Aristolochia spp. are immature and 
cannot contaminate wheat (16);
(ii) farmers from a BEN area usually bring sacks 
of wheat to the mill and exchange them for sacks of 
fl our from wheat produced by other farmers (17);
(iii) Moreover, Hranjec et al. (13) made a 
miscalculation which exaggerated estimated 
exposure in Croatian endemic villages to AA by 
a factor of 7;
(iv) in some countries, flour contamination 
hypothesis does not match the hilly topography of 
the endemic and non-endemic villages. In Romania 
Table 1 Epidemiological, clinical, and functional 
characteristics of BEN *
Epidemiological characteristics
Residence in an endemic settlement
Family history of renal disease and of renal 
deaths
Family history of urothelial tumours
Occupational history of farming
Clinical characteristics
Slowly progressive renal insuffi ciency
Anaemia - normochromic or slightly 
hypochromic
Oedema absent
Hypertension - rare in early, common in 
advanced renal failure
Urothelial tumours - common
Abnormalities on urinalysis
Reduced kidney size, normal size in early stages
Functional changes
Impaired concentrating capacity
Decreased glomerular fi ltration rate
Impaired urinary acidifi cation
Glycosuria, aminoaciduria
Increased uric acid excretion
Renal salt wasting
Proteinuria of the tubular type
*Modifi ed from Stefanovic (1)
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for example, maize is the dominant cereal, and 
maize cannot be contaminated by AA. Exposure 
to AA in specific nephropathy households of 
Croatian (and other) endemic villages has yet to 
be demonstrated;
(v) a high dose of AA (50 mg kg-1 b.w. per day, 
for three days) elicited a toxic response only in 
female rats, but renal function recovered within a 
month. After 6 months, three renal carcinomas were 
found in the exposed group, but no TCC (19);
(vi) rabbits receiving i.p. AA dose of 0.1 mg kg-1 
b.w. fi ve days a week for 17 to 21 months showed 
anorexia and lower weight gain, but also doubled the 
kidney weight, which is in contradiction with kidney 
atrophy observed in BEN patients (Table 2);
(vii) an analysis of p53 gene mutations revealed 
a statistically signifi cant difference between the 
mutation spectra in both the kidney and the liver 
of AA-treated rats, with transversion A:T → T:A 
accounting for 78 % of all base substitutions. A study 
of samples taken from 90 Bulgarian patients with 
BEN showed only 10 % of transversions (20);
(viii) several Aristolochia spp. have been used 
in Chinese medicine at much higher doses for over 
2000 years, and no case of nephropathy or urothelial 
cancer has been reported to correlate with the use of 
AA. In Germany, more than a thousand of patients 
had been using AA as immunomodulator for 25 
years without catching acute or chronic interstitial 
nephritis. The doses were similar to those reported 
in a weight loss regimen claimed to be responsible 
for the development of AAN (equivalent to the daily 
dose of 1.2 mg of AA) (21);
(ix) based on a study on mice which lasted 
for 28 days, Xue et al. (22) calculated that the 
no-observed effect level (NOEL) of exposure to 
Aristolochia manshuriensis Kom., Akebia trifoliate 
(Thunb.) Koidz., Akebia quinata (Thunb.) Decne and 
a traditional Chinese prescription called “Longdan 
Xieganwan” was 0.25 to 25 times the normal human 
dose in clinical prescription. Moreover, doses 400 
times higher than used in the weight loss regimen 
did not induce any symptoms (22);
(x) rats with acute nephrotoxicity induced by 
Aristolochia manshuriensis (4 g kg-1 b.w. per day) 
did not show interstitial tubular damage (23, 24), 
contrary to findings in patients suffering from 
nephropathy after a slimming regimen;
(xi) in a Belgian study (25) only 100 of 1741 
subjects who were taking slimming medication 
developed extensive interstitial fibrosis of the 
kidneys, the so-called Chinese herbs nephropathy. 
The disease did not correlate with the length of 
treatment. In an extensive review of Chinese 
herbs nephropathy, Meyer et al. (26) reported that 
slimming herbal preparations usually contained 
a mixture of ingredients of plant origin and other 
active substances, including fenfl uramine (agonist of 
serotonine) and diethylpropion (sympathomimetic), 
which are powerful renal vasoconstrictors. They can 
induce renal ischemia, which in turn could amplify 
the nephrotoxicity of AA. The same authors noted 
that glomerular vasoconstriction in rats was observed 
in studies where serotonine induced ischemic 
nephritis without any effects on the medulla. 
These arguments suggest that fenfl uramine could 
be responsible for interstitial nephritis evolving 
into interstitial fi brosis. Moreover, the slimming 
medicaments often contained acetazolamide, which 
also could increase nephrotoxicity (26).
CANCERS RISK: OTA VS. AA
OTA is one of the most potent renal carcinogens 
found to date (27, 28). Previous studies indicate that 
renal carcinoma metastases occurred mainly in the 
lungs and mammary glands of both male and female 
rats. An unusually high rate of 37 % was observed 
in male rats treated with 210 µg kg-1 b.w. of OTA. 
High-dosed female rats showed a signifi cantly 
higher incidence of fi broadenomas of the mammary 
gland than controls (56 % vs. 34 %; N=50). They 
also had a higher incidence of multiple mammary 
fi broadenomas (two per animal) than controls (28 % 
vs. 8 %; N=50) (27). Higher incidence of mammary 
proliferative lesions was also found in another study 
of OTA-treated female Lewis rats (29).
These results were confi rmed by a study of 
Lewis and Dark Agouti (DA) rats (30). Male DA 
rats were very sensitive to OTA-induced renal 
adenocarcinoma, whereas female DA rats were 
resistant. In addition, male DA rats were much 
more sensitive than either male or female Lewis 
rats. This difference in sensitivity may be due to 
differences in biotransformation capacity of OTA 
(31). In a recent study by Mantle et al. (32), OTA 
(100 µg per day) was administered to male Fisher-
344 rats by gavage. The fi rst tumour was recorded 
after 75 weeks of treatment. 20 % of rats developed 
renal carcinoma, mostly associated with metastatic 
nodules situated along the abdominal mesenteries, 
while some tumours spread to the lungs as well. The 
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authors also found other histopathological changes 
in the kidney such as karyomegalic nuclei in tubular 
epithelia, predominantly in the cortico-medullary 
region (32). The same authors reported that less 
than 10 months of dietary consumption of OTA 
in the fi rst year of life suffi ced for development 
of unilateral or bilateral renal tumours in some 
individuals after a latency of about a year (33). We 
also showed that OTA transplacental contamination 
of mice led to kidney tumours in male pups 9 
months after birth (34).
Table 2 lists data about acute and subchronic 
toxicity of aristolochic acids I and II (35-40). 
Unlike OTA, AAs are mainly carcinogenic for the 
forestomach. Cosyns et al. (16) reported that Wistar 
rats receiving AA isolated from herbal slimming 
medication for three months developed tumour of 
the forestomach, but did not develop nephropathy. 
These data were confi rmed by Chang et al. (41) who 
treated male Wistar rats with a mixture of aristolochic 
acids did not observe any impairment of the kidney 
function, interstitial nephropathy, or carcinoma.
CLINICAL CHARACTERISTICS AND 
PATHOLOGY OF NEPHROPATHY 
INDUCED BY OTA AND AA
OTA has been suspected to be involved in BEN, 
a human disease characterised by progressive renal 
fi brosis and associated with tumours of the urinary 
tract such as carcinoma of the renal pelvis, ureters, 
and bladder (42-44). Kidney fi broma, adenoma, or 
fi broadenoma have been reported in Bulgarian pigs 
with mycotoxic progressive nephropathy (MPN) 
(45-47). Stoev (48) found a positive correlation 
between the frequency of spontaneous porcine 
nephropathy and the rate of OTA contamination 
of feed samples which were not properly stored on 
farms. The frequency and duration of nephropathy 
in batches of slaughtered pigs depended on the 
duration of feeding on suspected feeds stored in 
poor conditions and at high humidity for a long 
time. Recently, Ceci et al. (49) showed that pigs 
from the Apulia region (Italy), fed on highly 
contaminated by OTA (149  µg kg-1 to 327 µg kg-1) 
accumulated a high amount of OTA in the kidney 
and urinary bladder, and developed macro- and 
microscopic lesions of the kidney (plurinucleate 
cells with hyperchromic nucleus and vacuolar 
degeneration of cytoplasm; karyomegaly and 
granular degeneration of the proximal tubule 
epithelium; hypercellularity and thickening of the 
capillary glomerular walls) and urinary bladder 
(mucosal hyperaemia and wall thickening; 
precancerous changes such as karyorrhexis, large 
nuclei, and hyperchromic nucleoli) (49). Likewise, 
the study on slaughtered pigs in Serbia confi rmed 
the implication of accumulated OTA in porcine 
nephropathy. Histopathological analyses of porcine 
kidneys proved tubulopathies with oedema, cell 
vacuolisation and necrosis of the proximal tubules. 
The highest amount of OTA was found in the kidney, 
and the severity of nephritis highly correlated with 
the OTA level (50). It is important to stress that 
porcine kidney damages in spontaneous MPN in 
Bulgaria (48) and in Serbia (50) were more similar 
to those observed in human endemic nephropathy 
patients in the Balkan countries than in Danish 
MPN. As the OTA amount in feed was almost 
fi ve times lower than the amount associated with 
Danish MPN, the authors (48, 50) concluded that 
kidney damage was caused by a synergistic effect 
of OTA and other mycotoxins. Pathomorphological 
changes in pig’s kidney experimentally exposed to 
OTA and penicillic acid (PA) were more similar 
to spontaneous MPN than to Danish MPN (51). A 
similar comparison was made between spontaneous 
mycotoxic avian nephropathy (MAN) and kidney 
damage in chicks receiving both toxins through 
diet (52). In addition, analyses of feed given to 
pig which suffered from kidney lesions confi rmed 




) (up to 
40 mg kg-1) (53).
Several experiments have clearly shown an 
additive or synergistic effect of OTA and other 
mycotoxins (54-57).
In a rodent study (58), we have demonstrated 
that citrinin (CTN) and OTA affected each other’s 
toxicokinetics. CTN favoured the excretion of 
the toxins, resulting in a decrease of both CTN 
and OTA storages in the liver and kidney, but the 
decrease was not similar in all tissues. This could be 
explained by competition between the toxins for the 
transporters of organic anion (OAT). Moreover, co-
exposure to OTA and CTN simultaneously modifi es 
DNA adduct formation with increasing formation 
of the C-C8 dG-OTA adduct (58). In an analysis of 
OTA and CTN levels in a human double diet study 
in Serbia, we observed that contamination of CTN 
depleted OTA via urine (59).
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5 mg kg-1 b. w. of 
AAs mixture per 
animal (77.2% AA I 
and 21.2% AA II in 
NaCl),
Treatment: 3 weeks
Follow up for 56 
weeks.
Animals were killed 
at weeks W3, W9, 




At W18 and W26, low to middle-grade papillomatosis in the 
forestomach of all animals, but no signs of malignancy.
W37 and W48; 1/5 of mice had squamous cell carcinoma.
Adenocarcinoma of glandular stomach observed in 1 mouse 
at W37.
Carcinoma of the forestomach observed in all mice killed at 
W56; adenoma of the kidney cortex (6/8), lung carcinoma 
(8/8), malignant lymphoma (4/8), and uterine haemangioma 
(3/8) were also observed.









Daily doses of AA 
extract in water: 
0.2 mg kg-1 b. w.; 
1.0 mg kg-1 b. w.; 
5.0 mg kg-1 b. w. and 








At the highest dose 25 mg kg-1 b. w. per day: decrease in 
weight and death of 2 animals.
Decrease in mean corpuscular volume, number of 
reticulocytes, total serum protein, and glycaemia. Increased 
proteinuria and glycosuria.
Atrophy of the thymus and spleen, hepatocellular basophila, 
infl ammation of the forestomach hyperplasia, nephritis, and 
testicular degeneration.
In the bladder; mild urothelial hyperplasia and slight cystitis.
At 5 mg kg-1 b. w. per day: Changes similar to the higher 
dose, but lower intensity.
At 1 mg kg-1 b. w. per day: mild changes
At 0.2 mg kg-1 b. w. per day : no modifi cations.











injection of AA 
mixture per animal 
(40 % AA I and 60 % 
AA II dissolved in 
polyethylene glycol 
and then diluted in 
water)
Low-dose group: 1.0 
mg kg-1 b. w. per day
High-dose group: 10 






urinary excretion of 
glucose, creatinine 







On days 10 and 35.
At 10 mg kg-1 b. w. per day: decreased body weight; 
glycosuria, proteinuria, increased creatinine level and 
decreased urinary leucine aminopeptidase activity on days 10 
and 35.
Tubular necrosis associated with infi ltrations of lymphocytes 
on day 10 and tubular atrophy with interstitial fi brosis on day 
35.
At 1 mg kg-1 b. w. per day : no signifi cant effects in 
biochemical parameters compared to control.
In both groups: urothelial lesions and malignant 
fi brohistiocytic sarcoma at injection site after day 35.




30 male and 
30 female
Oral
0.1 mg kg-1, 1.0
mg kg-1 and
10 mg kg-1 b. w. of 
AA extract
(77.2% AA I and 
21.2% AA II) in form 
of its sodium salt.
Treatment: 
3 months, with 1.0 
mg kg-1 b. w. and 10 
mg kg-1 b. w., with 
a 3- and 6-month 
follow-up;
3 and 12 months with 
0.1 mg kg-1 b. w., 




At 10 mg kg-1 b. w. :carcinoma of forestomach in 13/18 males 
and 8/13 females treated for 3 months and killed at 6 months.
Carcinoma of the renal pelvis (8/18) in males; carcinoma of 
forestomach in 4/4 females treated for 3 months and killed at 
9 months.
At 1 mg kg-1 b. w.:
carcinoma of the forestomach only in 3/11 males treated for 3 
months and killed at 6 months.
Carcinoma of the forestomach in 6/9 males and 2/11 females 
treated for 3 months and killed at 9 months.
At 0.1 mg kg-1 b. w.: no abnormality detected at the end of the 
treatment.
Carcinoma of the forestomach only in 2/7 males treated 
for 3 months and killed at 12 months. Carcinoma of the 
forestomach in 4/4 males and 1/5 females treated for 12 
months and killed at 16 months.
Control: 1 tumour (spontaneous polyp of endometrium ) in a 
female.
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10 mg kg-1 b. w. of 
AA
(77.2 % AAI and 






Treated group: extensive necrosis of squamous cells of fore
stomach followed by regeneration and
hyperplasia, formation of papilloma and,
invasive carcinoma of squamous cells.
Control group: no effect.













0.1 mg kg-1 b. w. 
of AA dissolved in 
saline
Treatment: 5














Growth decrease, increased serum creatinine, glucosuria, 
tubular proteinuria, and anaemia.
Kidney fi brosis in all animals: interstitial fi brosis.
Two animals developed kidney tumours (carcinoma of renal 
cells and tubulo-papillar adenoma).
1 case of cellular carcinoma of ureter and 1 peritoneal 
mesothelioma.
OTA-DNA VS. AA-DNA ADDUCT 
FORMATION
As early as 1993, we detected specifi c OTA-DNA 
adduct in kidney and bladder tumours of Bulgarian 
patients with BEN and associated UTT (60). 
Interestingly, we observed the same DNA adduct 
patterns in pig, chicken and human kidney, the last 
from affected households in Bulgaria (Figure 1). 
Detection of DNA adducts by postlabelling allows 
us to get an insight into the metabolic pathways 
involved in the genotoxicity of OTA (Figure 2; 43, 
62). OTA-covalent-DNA adducts are formed after 
biotransformation into quinone derivatives (63). 
The main adduct, C-C8dG OTA, has recently been 
identifi ed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) in the kidney of a patient 
with BEN and UTT and in an animal fed with OTA 
(64-66). Increasing intake of OTA increases OTA-
DNA adducts formation, notably in pig (Figure 3A) 
Several OTA derivatives have been identifi ed in 
blood, urine, and tissues (Figure 3B). Metabolites 
found in blood and urine of Serbian men and women 
from BEN families were similar to OTA derivatives 
found in rats and pigs (Figure 4). Men and male 
rat have more metabolites in blood than female 
rat and women, who in contrast eliminate them 
more effi ciently. A positive correlation is observed 
between the intake of OTA and these metabolites 
(data not shown).





) further enhances OTA-DNA adduction 
in pigs. The DNA adduct pattern is similar to that 
observed in some Croatian patients with BEN and 
UTT (Figure 5). In a study on rats, we demonstrated 
the genotoxicity of OTA even with a dose that 
was considered safe (5 ng kg-1 b.w. per day). OTA 
genotoxicity dramatically increased when rat are 
exposed simultaneously at 200 ng kg-1 b.w. of 
FB
1
 per day and even more at 50 µg kg-1 b.w. of 
FB
1
 per day (Figure 6). Exposure to a higher OTA 
dose (50 µmol L-1) resulted in a lower number of 
DNA adducts than exposure to lower doses. This is 
because at 50 µmol L-1 OTA is cytotoxic, and thus 
DNA adduction is indirectly lowered.
Therefore, chronic exposure low OTA doses 
could be much more damaging than acute exposure 
to a high dose. Analyses of several DNA adducts 
in patients with transitional cell carcinomas from 
different European countries show that 30 % of 
the kidney carcinoma could be attributed to OTA 
intake (59).
In 1994, Wiessler (61) suggested that AA could 
not cause BEN and that AA-DNA adduct was never 
found in humans, even though AA had been used 
in therapy for decades. Surprisingly, two years 
later Schmeiser et al. (67) claim that AA-DNA 
adduct was detected in Belgian women suffering 
from Chinese herbs nephropathy after a slimming 
regimen even though AA was not found in the pills 
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Figure 3  Kidney DNA adduct pattern of a pig fed with 
increasing amounts of OTA for 6 months (A); OTA 
derivatives excreted in pig urine (B). DNA adducts 
were separated using the contact transfer method and 
OTA solvents: D1 - 2.3 mol L-1 sodium phosphate, pH 
5.7; D2 - 4.77 mol L-1 lithium formate, 7.65 mol L-1 
urea, pH 3.5; D3 - 0.6 mol L-1 sodium phosphate, 
5.95 mol L-1 urea, pH 6.4; D4 1.7 mol L-1 sodium 
phosphate, pH 6
Figure 1  Kidney DNA adduct pattern of a pig (A, C); chicken (B, 
D); a Bulgarian farmer (E); and the DNA adduct of the 
bladder of a Bulgarian farmer (F) suffering from BEN 
and UTT. (A) and (B) correspond to pig and chicken 
from a Bulgarian farm; (C) and (D) correspond to a 
pig and chicken fed with OTA in feed for 6 months. 
DNA adducts were separated with the contact transfer 
method using OTA solvents: D1 - 2.3 mol L-1 sodium 
phosphate, pH 5.7; D2 - 4.77 mol L-1 lithium formate, 
7.65 mol L-1 urea, pH 3.5; D3 - 0.6 mol L-1 sodium 
phosphate, 5.95 mol L-1 urea, pH 6.4; D4 - 1.7 mol L-1 
sodium phosphate pH 6
Figure 2  Metabolic pathway of OTA.
OTA - ochratoxin A; OTB - dechlorinated ochratoxin; OP-OTA - open ring ochratoxin; OTHQ - ochratoxin 
hydroxyquinone; OTSQ - ochratoxin semiquinone, OTQ - ochratoxin quinone; ROS - reactive oxygen species; LPO 
- lipoperoxydes; C-C8 dG OTA - deoxyguanosine ochratoxin adduct
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they had been taking and they stopped the treatment 
several months or years ago (67). DNA adducts 
have been described in only eight of 100 Belgian 
patients who developed nephropathies following 
a slimming regimen. These data were published 
three times and were the basis to declare AA 
472
Figure 4  Blood (B) and urine (C) OTA derivatives in men and 
women belonging to BEN families compared to rat 
urine (A).OTA ochratoxin A; OTHQ hydroxyquinone 
ochratoxin ;OTB dechlorinated ochratoxin; OP-OTA 
open ring ochratoxin; GSH glutathione conjugate; 
NAC N-acetylcystein; DC OTA decarboxylated 
ochratoxin; DCOTHQ decarboxylated ochratoxin 
quinone
Figure 5  Kidney DNA adduct pattern of a pig fed with FB
1
 and/or OTA and the kidney DNA adduct of a Croatian farmer suffering 
from BEN: A - control; B - pig fed with FB
1
; C - pig fed with OTA; D - pig fed with FB
1
 and OTA; and E - Croatian 
farmer. DNA adducts were separated using the contact transfer method and OTA solvents: D1 - 2.3 mol L-1 sodium 
phosphate, pH 5.7; D2 - 4.77 mol L-1 lithium formate, 7.65 mol L-1 urea, pH 3.5; D3 - 0.6 mol L-1 sodium phosphate, 
5.95 mol L-1 urea, pH 6.4; D4 - 1.7 mol L-1 sodium phosphate, pH 6
Figure 6  Kidney DNA adduct pattern in a rat fed with OTA 
alone (black) or OTA and FB
1
 (hatched grey) for 
four weeks. OTA intake was 5 ng kg-1 b.w. per day or 
50 µg kg-1 b.w. per day. FB
1
 intake was 200 ng kg-1 
b.w. per day or 50 µg kg-1 b.w. per day. DNA adducts 
were analysed using the method described in Figures 
1, 3, and 5.
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responsible of Chinese herb nephropathies (67-69). 
Furthermore, questionable is the presence of DNA 
adducts at a level as high as fi ve adducts per 107 
nucleotides several years after the intake stopped. 
Most of the cells would have been replaced after 
several months even in slowly renewing tissues 
such as the kidney and even if no repair occurred. 
A simple calculation can show that if these 
hypotheses were true all the molecules of DNA 
would be adducted! Surprised by this fi nding, we 
compared the formation and repair of DNA adduct 
in human renal cells treated with either OTA or 
AA. Neither pure AA I nor a mixture of AA I and 
AA II induce DNA adducts to a higher extent than 
OTA. These DNA adducts are repaired as quick 
as OTA DNA adducts, and thus they could not be 
found several months after AA intake had stopped 
(59). To investigate the strange results published by 
Schmeiser et al. we analysed their publications in 
depth. For better understanding, Figure 7 describes 
different methods of DNA adduct separation. 
Figure 8 shows a drawing of different DNA 
adduct patterns. In the fi rst publication, Schmeiser 
et al. noted only one DNA adduct attributed to 
dA-AA I (7-deoxyadenosin-N6-yl)-aristolactam I 
in the kidney of Belgian woman who followed a 
slimming regimen (Figure 8A) whereas Arlt et al. 
(69) observed a number of DNA adduct patterns in 
the same Belgian patient, either using the contact 
transfer method and OTA separation solvents 
(fi gure 8D) or the multidirectional method and 
AA separation condition (Figure 8B). Both types 
of DNA adducts (OTA and AA) were observed 
using OTA solvents (Figures 8D, 8E, and 9F). In 
5 ng kg-1 OTA 5 ng kg-1 OTA +
200 ng kg-1 FB
1
5 ng kg-1 OTA +
50 μg kg-1 FB
1
50 μg kg-1 OTA 50 μg kg-1 OTA +
50 μg kg-1 FB
1
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contrast, specifi c OTA adducts were lost using AA 
solvents and the contact transfer method (Figure 
9D). The absence of AA-related DNA adducts 
in Figure 8E and 8F is not possible, as they are 
observed in the other migration systems (Figure 
8B and 8C). In contrast, OTA-related adducts 
were not lost when multidirectional method was 
used whatever, regardless of the migration solvent 
(Figure 10). In the AA solvent migration system 
using the multidirectional method we observed 
two to four adducts OTA-related adducts (called 
X1 to X4). The main adducts X3 and X4 were 
found in the Belgian samples (Figure 8B), but also 
in a Croatian patient (Figure 8C) and in a French 
patient described in Arlt’s et al. (70). Nevertheless, 
the authors did not make any comments about the 
presence of these OTA-related adducts. To our even 
greater surprise, using the contact transfer method 
and OTA solvent they observed only OTA-related 
DNA adducts, and we wonder how they then found 
AA related adducts! A careful analysis of the DNA 
adduct pattern using different methods of separation 
is essential to avoid any misinterpretation. Grollman 
et al. (71) concluded that EN was caused by AA 
based on the DNA adduct pattern in four patients 
detected using Polyacrylamide Gel Electrophoresis 
(PAGE). However, this method is questionable 
for two reasons: (i) DNA was extracted using a 
commercial Qiagen® kit, and we have shown that 
this type of extraction usually gives low DNA 
purity (34, 66) and (ii) detection was based on the 
comparison of bands, but the standard AA adduct 
bands were so wide that the faint band seen in the 
sample coincided with them.
The data published by Arlt et al. (72) are 
doubtful and contain misinformation about the 
women who have followed a slimming regimen. 
In addition to herbal pills, these women were 
taking several other drugs including amfepramone 
and mesotherapies (but they did not describe their 
composition). This information was also lacking 
in a paper by Stengel and Jones (73). We analysed 
DNA samples of both women using two different 
chromatographic separation (OTA solvents versus 
AA solvent). One patient clearly showed OTA-
DNA adducts but no AA-DNA adduct, and the other 
showed no adduct whatsoever (59). Moreover, only 
small quantities of AA, if any, could be detected 
in the pills, and calculations based on equivalent 
human dose indicate that to reach the toxic dose 
the women should have been taking 150 mg of 
Figure 7  DNA adduct detection using the multidirectional 
method (A) or contact transfer method (B). The 
solvents migration systems used for AA separation 
were the following: D1 - 1 mol L-1 sodium phosphate 
; D2 - 3.5 mol L-1 lithium formate, 8.5 mol L-1 urea, 
pH 3.5; D3 - 0.8 mol L-1 lithium chloride, 0.5 mol L-1 
Tris-HCl, pH 9.1; D4 - 1.7 mol L-1 sodium phosphate, 
pH 6. OTA solvents were: D1 - 2.3 mol L-1 sodium 
phosphate, pH 5.7; D2 - 4.77 mol L-1 lithium formate, 
7.65 mol L-1 urea, pH 3.5; D3 - 0.6 mol L-1 sodium 
phosphate, 5.95 mol L-1 urea, pH 6.4; D4 - 1.7 mol L-1 
sodium phosphate, pH 6
Figure 8  DNA adduct patterns described in papers referenced 
under 68-71. Schemes A to C correspond to the DNA 
adduct pattern obtained using the multidirectional 
method and aristolochic acid solvents: (A) Belgian 
kidney published in references 68, 69 (B) Belgian 
kidney published in reference 70 (C) Croatian kidney 
published in reference 71. Schemes D-F correspond 
to DNA adduct patterns from the same samples as A-
C, using transfer contact method and OTA solvents: 
(D) Belgian kidney published in reference 70 (E); 
Belgian kidney published in reference 59 (F); and 
Croatian kidney published in reference 71
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been demonstrated that either Belgian women or 
French women were not taking herbal pills alone, 
but also many other substances (75)
GENETIC POLYMORPHISMS AND OTA
Since recently, genetic polymorphisms of 
some xenobiotic-metabolising enzymes have been 
associated with BEN (76). A signifi cantly higher 
risk of BEN (OR 2.41, 95% CI 1.09 to 5.33) was 
observed in individuals carrying the CYP 3A5*1 
allele . CYP 3A are the most common enzymes in 
the liver. The prevailing form of CYP 3A in the 
kidney is CYP 3A5, especially in the proximal 
tubule. A link between CYP 3A5 expression 
and renal metabolism of endogenous factors has 
been also suggested (77-79). Its expression is 
polymorphic in the liver, intestine, and kidney. CYP 
3A5*1 (adenine at position 6986) is related to an 
enhanced protein expression (so-called expressor 
allele), while guanine at the same position (CYP 
3A5*3) leads to absence or defect of this CYP 
protein (non-expressor allele). The carrier of the 
CYP 3A5*1 allele may have the ability to more 
effi ciently convert OTA into genotoxic metabolites 
that provoke BEN and create an individual 
predisposition to the disease.
OTA induces mutation on the lacZ gene in NIH/
3T3 cells transfected with distinct human CYP450 
Figure 9  Kidney DNA adduct pattern of a rat fed with OTA 
(A, D); AA (B, E); and co-migration of OTA and 
AA (C). DNA separation using the transfer contact 
method either with OTA solvents (D1 - 2.3 mol L-1 
sodium phosphate, pH 5.7; D2 - 4.77 mol L-1 lithium 
formate, 7.65 mol L-1 urea, pH 3.5; D3 - 0.6 mol L-1 
sodium phosphate, 5.95 mol L-1 urea, pH 6.4; D4 - 
1.7 mol L-1 sodium phosphate, pH 6) (A-C) or with 
AA-solvents (D1 - 1 mol L-1 sodium phosphate; D2 
- 3.5 mol L-1 lithium formate, 8.5 mol L-1 urea, pH 
3.5; D3 - 0.8 mol L-1 lithium chloride, 0.5 mol L-1 
Tris-HCl, pH 9.1; D4 - 1.7 mol L-1 sodium phosphate, 
pH 6) (D-F).
Figure 10  Kidney DNA adduct pattern in a pig (A, E), chicken (B, F), and a rat (C, G) fed with OTA; and in a human with UTT 
and having OTA in blood, urine, and tissue (D, H). DNA adducts were separated using the multidirectional method 
and OTA solvents (D1 - 2.3 mol L-1 sodium phosphate, pH 5.7; D2 - 4.77 mol L-1 lithium formate, 7.65 mol L-1 urea, 
pH 3.5; D3 - 0.6 mol L-1 sodium phosphate, 5.95 mol L-1 urea, pH 6.4; D4 - 1.7 mol L-1 sodium phosphate, pH 6) (A-
D); or AA solvents (D1 - 1 mol L-1 sodium phosphate; D2 - 3.5 mol L-1 lithium formate, 8.5 mol L-1 urea, pH 3.5; D3 
- 0.8 mol L-1 lithium chloride, 0.5 mol L-1 Tris-HCl, pH 9.1; D4 - 1.7 mol L-1 sodium phosphate, pH 6) (E-H)
AA, that is, 416 pills a day! The persistence of 
AA-DNA adduct eight years after the treatment is 
also hard to believe (74). In addition, it has clearly 
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enzymes. This mutation is more pronounced in the 
presence of CYP 2C9 (81). Implication of CYP 
2C9 in OTA genotoxicity has been shown in cell 
culture (82) and in rats (31), and is related to the 
ability to metabolize debrisoquine. It has been 
observed that individuals having high capacity 
to metabolized debrisoquine are more frequent in 
BEN patient compared to individuals non affected 
by BEN (80)
Many studies have assessed the risk of different 
diseases, and bladder cancer in particular, in relation 
to glutathione S-transferase (GST) (83-86).
In a Bulgarian study (87) carriers of at least one 
GSTM1 wild-type allele (positive conjugators) were 
more prevalent among BEN patients than among 
controls (chi-square=7.92, p=0.005). In general, 
conjugation of xenobiotics with glutathione (GSH) 
leads to detoxifi cation. However, some data show 
that certain GSH conjugates could be nephrotoxic 
such as halogenated derivatives, hydroquinones (88, 
89) or OTA. (43). We have demonstrated that both 
oxidative stress and covalent binding are involved in 
OTA nephrotoxicity and carcinogenicity (90) while 
Faucet-Marquis et al. (91) established a correlation 
between DNA adducts and OTA derivatives in an 
opossum kidney cell culture (91).When applied to 
renal tubular cells, OTA led to GSH depletion (92). 
Using primary human urothelial cells from several 
donors, Lebrun et al. (93) pointed out the role of 
genetic GST expression and the extent of DNA 
damage induced by OTA. GSTT1 positive genotype 
was more frequently observed in the subgroup 
with DNA damage induced by OTA compared to 
subgroup without DNA damage. The effect of GSH 
on OTA toxicity is dual: GSH favour detoxifi cation 
rate of ROS and thus depletion will be deleterious 
for the kidney; in contrast GSH will not decrease 
carcinogenicity as some GSH-conjugates are 
genotoxic (90, 94).
Excessive coffee consumption (more than 
three cups a day) was implicated in upper tract 
transitional cell carcinoma and bladder cancer (92, 
95, 96). The risk is higher for heavy coffee drinkers 
carrying the genotype GSTP1 105-104 val (96). 
This is important to stress, as coffee is one main 
source of OTA intake.
SOURCES OF CONTAMINATION WITH 
OTA
In all countries, farmers who consume their own 
food products are more affected by nephropathies 
and associated urothelial tract tumour (43, 97) 
than the general population. In the Balkan region, 
residents of BEN-affected households often live in 
close proximity of poultry and pig husbandry. As 
the feed is stored without any precaution, both the 
residents and the animals are exposed to airborne 
dust. Therefore, inhalation of mycotoxins is an 
additional risk source (98).
Exposure through food
Barley, wheat, maize, rice (99), nuts, beers, cocoa, 
spices, milk, and pork (43) could be contaminated 
by OTA and other mycotoxins. There is a large 
body of papers documenting OTA contamination 
of green and processed coffee and reporting 
OTA-producing fungal isolates from coffee. OTA 
contamination of commercial, packaged coffee is 
very common, despite the fact that over half of 
OTA is destroyed by roasting (100-102). OTA 
frequently co-occurs with other mycotoxins. Multi-
mycotoxin aetiology of MPN/MAN was recently 
confi rmed in Bulgaria (52). High contamination 
with PA [(838.6±223.9) µg kg-1; 88 % samples 
positive] and FB1 [(5564.1±584) µg kg-1; 96 % 
positive samples] was found in feed samples 
from Bulgarian farms with MPN associated with 
a relatively low level of OTA (188.8±27.3) µg 
kg-1. A similar multi-mycotoxin aetiology was 
also found for South African MPN (52). The 
following levels were found in feed samples 
from pig farms with nephropathy problems: OTA 
(67.8±39.2) µg kg-1 (80 % samples positive); PA 
(149.2±64.1) µg kg-1 (41.7 % samples positive); 
and FB
1
 (5046.7±1301) µg kg-1 (80 % samples 
positive).
Co-occurrence of OTA and fumonisins was 
reported in Croatia (103) and several countries in 
the Balkan region (104). Co-occurrence of OTA 
and CTN was reported in Bulgaria (105-107). 
Vrabcheva et al. (105) observed co-occurrence of 
OTA and CTN in BEN families. The amount of 
CTN was about fi ve times higher than OTA. We 
also observed that BEN families in Serbia were 
co-exposed to OTA and CTN, but CTN exposure 
was not found in non-BEN families (59).
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Exposure through inhalation
Historically, airborne OTA poisoning is 
related to the “old book disease” and the “curse 
of Tutankhamun”. Several archaeologists who 
opened ancient Egyptian tombs died suddenly and 
mysteriously of unexplained causes. It has been 
suggested that the cause of death was acute renal 
failure due to inhalation of spores (Aspergillus 
ochraceus) which contained ochratoxins (108).
Agricultural workers are often exposed 
to airborne OTA when they manipulate with 
stored wheat, especially if it is kept in a closed 
compartment for longer time. Farm workers are 
exposed to contaminated airborne aerosols when 
they tend cows or work with mouldy feed and 
bedding materials.
It has recently been demonstrated that OTA is 
present in spores and airborne dust (109-110). A 
study conducted of three dairy farms in Norway 
(110) showed OTA in airborne dust ranging between 
0.2 µg kg-1 and 70 µg kg-1, with an average level of 
27.5 µg kg-1. Two Italian studies (111, 112) have 
demonstrated human exposure to OTA from dust at 
workplace and reported a relation between airborne 
OTA and OTA levels in workers’ blood. The levels 
of airborne OTA in the handling and processing 
areas were higher than in offi ce air. Serum OTA at 
the end of the work shift was signifi cantly higher 
(0.94 ng mL-1 to 3.28 ng mL-1) than in the control 
group of workers (0.03 ng mL-1 to 0.95 ng mL-1) 
(111). Another study reported that serum OTA in 
malt factory workers increased with exposure to 
dusts and were higher in the autumn, after grain 
delivery, than in the summer (113).
A recent air analysis of a poultry house revealed 
not only OTA, but also afl atoxins and zearalenone 
(ZEA) (114). The authors calculated that a poultry 
worker breathed in up to 600 ng of mycotoxins in 
a working day, of which OTA accounted for 68.24 
ng. In another study, air analysis of grain storage 
showed 2 pg m-3 of OTA, 2 ng m-3 of DON, and 
1 ng m-3 of ZEA (98).
OTA in combination with either sterigmatocystin 
or citrinin has often been found in stored wheat, 
barley, oat, and corn (115). Analyses of different 
commodities including raw foodstuffs and processed 
food in Belgium have shown that 40 % of samples 
contained up to 25 µg kg-1 of OTA (116). In settled 
dust collected ingrain storages, 104 ng m-3 of OTA 
and 244 ng m-3 were detected (117). In Europe, 
cereals are frequently stored at the farm for economic 
reasons (low price, use as feed). This increases the 
risk of exposure to mycotoxins because harvested 
grains are not always low in moisture to prevent 
fungal growth during the storage. Puissemier et al. 
(118) have reviewed data from different countries 
and concluded that atypical severe contaminations 
of cereals by OTA (up to 1000 µg kg-1 measured 
in Poland on one occasion) could be related to bad 
storage conditions in individual farms. We also 
observed the highest contamination with OTA and 
CTN in wheat stored at farms in France (59). During 
milling, dust particles may be dispersed in the 
environment and increase exposure to mycotoxins 
by inhalation among grain workers (119). As 
storage work generates fi ve times more dust through 
threshing, it is considered an important exposure 
factor (120). Dust of contaminated products usually 
contains mycotoxins in greater quantities that the 
products themselves (113). In a hyper-endemic 
former Yugoslav community, nephrotoxic species 
of Penicillium were also isolated from air samples 
(121).
Exposure through water
Filamentous fungi have recently been reported to 
contaminate drinking water (122, 123) Aspergillus 
spp. (notably A. fumigatus), Cladosporium spp., 
Fusarium spp. and Penicillium spp. (mainly P. 
citrinum, P. glabrum, P. restrictum, P. expansum) 
were the prevalent species. Many of the identifi ed 
fungal species are known to produce toxic 
secondary metabolites in different matrices. For 
example 35 of 61 of Fusarium species produced 
fumonisins and zearalenone (122). Aflatoxins 
produced by Aspergillus fl avus were also detected 
in water sampled from a cold water storage tank 
(123). This kind of contamination is low in normal 
domestic tap water. Problems arise when water 
is stored in cisterns or wells, where mycotoxin 
concentration is much higher (123) This could 
explain the reported correlation between BEN and 
the use of wells (97).
CONCLUSION
Thirty years of research clearly show that 
mycotoxins, and OTA in particular, play a major 
role in some nephropathies and associated urothelial 
tract tumours in rural population all over the world. 
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In rural economies, one tends to eat what one grows, 
including the pigs that feed on the same grain. 
This may result in high chronic exposure to OTA 
(124). Average European daily intake of OTA has 
been estimated to 0.7 ng kg-1 to 4.6 ng kg-1 of body 
weight, with over half of the OTA coming from 
cereals (125). However, in the Balkan endemic 
areas the intake is around 100 µg kg-1 b.w. per day. 
This explains the prevalence of EN in these areas.
Individuals from other countries all over the 
world are often exposed to low OTA doses, which 
still exceed the putative safety limit of 1.5 ng kg-1 
b. w. per day, established by Kuiper-Goodman 
et al. (126), and which may lead to urothelial 
tract tumours. Particularly vulnerable are people 
sensitive to OTA due to genetic polymorphisms, 
but also those who have been exposed to OTA 
during prime childhood. Because of their lower 
body weight, young children could be exposed to 
OTA doses three times as high as adults, suffi cient 
to cause kidney damage, which could go unnoticed 
for a while, as the kidney has a large functional 
reserve. When the accumulated damage reaches a 
threshold, the kidney function may deteriorate to 
the end-stage renal failure (125).
Human exposure to OTA is mainly through 
food, but also through inhalation and drinking 
water, the last mainly in rural areas, and mainly 
to well water, which has been corroborated by the 
correlation between BEN and wells used.
OTA seems to be also a critical agent in Canada 
where 4,300 new cases of kidney cancer appeared 
per year (National cancer Institute Canada, 2004). 
The affect mainly male (63%).
The highest kidney cancer incidence rate was 
found in Manitoba (127), and it correlated with 
male individuals who had the highest blood plasma 
levels of OTA (128).
Moreover, co-exposure to OTA and other 
mycotoxins such as fumonisins and citrinin increase 
the risk, as it has been demonstrated in Croatia and 
Bulgaria. Interestingly, the kidney DNA adduct 
pattern of BEN patients is similar to the kidney 
DNA adduct pattern of pigs living in the same farm 
and of pigs co-exposed to OTA and fumonisins or 
citrinin. These promote biotransformation of OTA 
into quinone derivatives, which are responsible for a 
specifi c OTA covalent DNA adduct, C-C8dG OTA, 
recently identifi ed by ms/ms (66). The correlation 
between OTA intake and the levels of OTA 
derivatives in the urine of on Serbian people and 
complete absence of AA (18, 59) or its derivatives 
corroborate the association between OTA and not 
AA and EN.
Despite clear evidence of implication of OTA 
and other mycotoxins in the development of 
nephropathy and urothelial tract tumour, IARC 
and FDA are reluctant to consider OTA as a 
human carcinogen and the main cause of BEN and 
associated UTT. Until OTA is publicly denounced 
as the culprit, food industry will be saving on 
detoxification from mycotoxins. On the other 
hand, redirecting attention to AA as responsible 
for Belgian nephropathy gives the pharmaceutical 
industry an opportunity to increase sales of 
amphetamines in weight loss programmes.
However, economic reasons should not blur 
facts. Mycotoxins are a major health problem 
everywhere in the world, and it is urgent to develop 
preventing measures.
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Sažetak
SAZNANJA O ULOZI MIKOTOKSINA I ARISTOLOHIČNE KISELINE U NEFROPATIJAMA 
I PRIDRUŽENIM TUMORIMA MOKRAĆNOG SUSTAVA
Etiologija dijela nefropatija i srodnih im tumora gornjeg dijela mokraćnog sustava koji se 
dijagnosticiraju diljem svijeta, a posebice na prostoru Balkana, još nije razjašnjena. Rezultati 
istraživanja provedenih zadnjih 35 godina upućuju na mikotoksine, a posebice okratoksin A (OTA), 
kao glavne uzročnike. U posljednje vrijeme raspravlja se i o mogućoj ulozi aristolohičnih kiselina 
(AA). Svrha ovoga preglednog rada jest obrazložiti argumente koji govore u prilog uključenosti 
mikotoksina kao čimbenika odgovornih za nastanak navedenih bolesti te rasvijetliti zablude oko teze 
koja govori u prilog uključenosti AA kao mogućeg uzročnika. U članku se raspravlja o razlici između 
(i) epidemiologije endemske (balkanske) nefropatije (BEN) i nefropatije uzrokovane pod utjecajem 
aristolohične kiseline (AAN), (ii) karcinogenosti OTA i AA, (iii) kliničkim i patološkim učincima 
izazvanim pod utjecajem OTA i AA, (iv) izvorima kontaminacije s OTA (hrana, zrak, pitka voda), 
(v) nastanku DNA-adukata pod utjecajem OTA ili AA, (vi) ulozi genskog polimorfi zma i (vii) riziku 
za malu djecu.
KLJUČNE RIJEČI: bubreg, DNA-adukt, etiologija, genski polimorfi zam, karcinom mokraćnog 
sustava, kontaminacija, patološki učinci
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